Compare iShares MSCI Australia ETF (EWA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Australia ETF trades at $28.69, while Inovio Pharmaceuticals Inc trades at $1.16 (market cap $96.26M). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWA | INO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.26 | $2.87 |
52-Week Low | $24.95 | $1.05 |
Market Cap | — | $96.26M |
Enterprise Value | — | $67.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.66, down 0.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $28, while resistance clusters near $29. The stock lacks disclosed financial ratios, and a dividend of $0.40 is scheduled for June 2026. Recent news highlights Australian economic factors and sector-specific developments influencing sentiment.
The outlook is mixed, with technical strength offset by limited fundamental visibility. Risks include reliance on Australian market conditions and macroeconomic headwinds. Investment appeal hinges on future financial disclosures and broader market trends.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
